Current Hypertension Reports

, Volume 1, Issue 2, pp 170–177 | Cite as

Antihypertensive drugs and diabetic nephropathy

  • Philip S. Mehler
  • Robert W. Schrier


Diabetic nephropathy is the most common cause of endstage renal disease in the United States. Hypertension is a major risk factor that predisposes individuals with diabetes to the development of renal disease and is very common in patients with diabetes. The benefit of blood pressure control on the rate of progression of diabetic nephropathy is being increasingly demonstrated in both type 1 and type 2 diabetic patients. Angiotensin converting enzyme inhibitors have proven renoprotective benefits in human studies, but the results of studies with calcium channel blockers are somewhat inconclusive. The other classes of antihypertensives also may have certain indications in the population of patients with diabetic nephropathy. In this paper we will critically review current strategies for the treatment of hypertension in patients with established diabetic nephropathy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    The National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases: United States Renal Data System. 1993 Annual Data Report. March 1993, 55–67.Google Scholar
  2. 2.
    Vibetti G: Outcome variables in the assessment of progression of diabetic kidney disease. Kidney Int 1994, 45:S121-S124.Google Scholar
  3. 3.
    US Renal Data System: 1994 Report. Am J Kidn Dis 1994, 24:S48-S56.Google Scholar
  4. 4.
    Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with Enalapril in normotensive type 2 diabetics with microalbuminuria. Diabetes Care 1997, 20:1576–1581.PubMedCrossRefGoogle Scholar
  5. 5.
    Ruilope CM: Renoprotection and renin-angiotensin system blockade in diabetes mellitus. Am J Hypertens 1997, 10:325S-331S.PubMedCrossRefGoogle Scholar
  6. 6.
    Porush SG: Hypertension and chronic renal failure: the use of ACE inhibitors. Am J Kidney Dis 1998, 31:177–184.PubMedGoogle Scholar
  7. 7.
    Zimmet P, McCarthy D: The NIDDM epidemic: global estimates and projections. IDF Bulletin 1995, 40:8–16.Google Scholar
  8. 8.
    Bretzel RG: Can we further slow down the progression to end stage renal disease in diabetic hypertensive patients? J Hypertens Suppl 1997, 15:S83-S88.PubMedGoogle Scholar
  9. 9.
    Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US population: results from the third national health and nutrition examination survey. Hypertension 1995, 25:205–313.Google Scholar
  10. 10.
    Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria, and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976, 36:383–388.PubMedGoogle Scholar
  11. 11.
    Cheng SS, Wilson DM, Munn SR: Predictors of progression of diabetic nephropathy. Clin Transplant 1997, 11:334–336.PubMedGoogle Scholar
  12. 12.
    Tanaka Y, Atsumi Y, Matsuoka K: Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 1998, 21:116–120.PubMedCrossRefGoogle Scholar
  13. 13.
    Nielsen S, Rehling M, Schmitz A: Systolic blood pressure relates to the rate of decline of glomerular filtration rate in type II diabetes. Diabetes Care 1993, 16:1427–1432.PubMedCrossRefGoogle Scholar
  14. 14.
    American Diabetes Association: Clinical practice recommendations 1996: treatment of hypertension in diabetes. Diabetes Care 1996, 19:S107-S113.CrossRefGoogle Scholar
  15. 15.
    Parving HH, Hommel E, Smidt UM: Protection of kidney function and decrease in albuminuria by captropril in IDDM with nephropathy. BMJ 1988, 297:1086–1091.PubMedGoogle Scholar
  16. 16.
    MacKenzie HS, Brenner BM: Current strategies for retarding progression of renal disease. Am J Kidney Dis 1998, 31:161–170.PubMedGoogle Scholar
  17. 17.
    Cooper ME: Antihypertensive therapy and diabetic microvascular disease. Clin Exp Hypertens 1997, 19:769–778.PubMedGoogle Scholar
  18. 18.
    Kennefick TM, Anderson S: Role of angiotensin II in diabetic nephropathy. Semin Nephrol 1997, 17:441–447.PubMedGoogle Scholar
  19. 19.
    Yoshida H, Kon V, Ichikawa I: Polymorphisms of the reninangiotensin system genes in progressive renal diseases. Kidney Int 1996, 50:732–744.PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshida H, Kuriyama S, Atsumi Y, et al.: Angiotensin I converting enzyme gene polymorphism in NIDDM. Kidney Int 1996, 50:657–664.PubMedCrossRefGoogle Scholar
  21. 21.
    Fagerudd JA, Tanow L, Jacobsen P, et al.: Predisposition to essential hypertension and development of diabetic nephropathy in NIDDM. Diabetes 1998, 47:439–444.PubMedCrossRefGoogle Scholar
  22. 22.
    Jeffers BW, Estacio RO, Raynolds MV, et al.: Angiotensin-converting enzyme gene polymorphism in NIDDM and its relationship with diabetic nephropathy. Kidney Int 1997, 52:473–477.PubMedCrossRefGoogle Scholar
  23. 23.
    National High Blood Pressure Education Program Working Group: Report on primary prevention of hypertension. Arch Intern Med 1993, 153:186–208.CrossRefGoogle Scholar
  24. 24.
    Addis T: Glomerulonephritis: Diagnosis and Treatment. New York, NY: Macmillan; 1948.Google Scholar
  25. 25.
    Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood pressure control on the progression of clinical renal failure: Modification of diet in renal disease study group. N Engl J Med 1994, 330:877–884.PubMedCrossRefGoogle Scholar
  26. 26.
    Pedrinin MT, Levey AS, Lau J: The effect of dietary protein restriction in the progression of diabetic renal disease: a meta-analysis. Ann Intern Med 1996, 124:627–632.Google Scholar
  27. 27.
    The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment on the development and progress of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977–986.CrossRefGoogle Scholar
  28. 28.
    Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents progression of diabetic microvascular complication in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995, 28:103–117.PubMedCrossRefGoogle Scholar
  29. 29.
    Massy ZA, Kasiske BL: Hyperlipidemia and its management in renal disease. Curr Opin Nephrol Hyperten 1996, 5:141–146.CrossRefGoogle Scholar
  30. 30.
    Scandinavian Simvastatin Survival Study Subgroup: Analysis of diabetic subjects. Diabetes Care 1997, 70:469–471.Google Scholar
  31. 31.
    McBride P, Schrott HG, Plane MB, et al.: Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998, 148:1238–1244.CrossRefGoogle Scholar
  32. 32.
    Sawicki PT, Didjurgeit U, Muhlhauser I: Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994, 17:126–131.PubMedCrossRefGoogle Scholar
  33. 33.
    Mehler PS, Jeffers B, Biggerstaff S, et al.: Smoking as a risk factor for nephropathy in non-insulin-dependent diabetes. J Gen Intern Med 1998, 13:842–845.PubMedCrossRefGoogle Scholar
  34. 34.
    Turner R, Holman R, Stratton I: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38. BMJ 1998, 317:703–713. Emphasizes that blood pressure control is more effective than glycemic control for preventing worsening of nephropathy.Google Scholar
  35. 35.
    Mogensen CE: Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ 1998, 317:693–694.PubMedGoogle Scholar
  36. 36.
    Microablumin Collaborative Study Group, United Kingdom: Intensive therapy and progression to clinical albuminuria in patients with IDDM. BMJ 1995, 311:973–975.Google Scholar
  37. 37.
    Mehler PS, Jeffers BW, Schrier RW: Association of hypertension and complications in non-insulin dependent diabetes mellitus. Am J Hypertens 1997, 10:152–161.PubMedCrossRefGoogle Scholar
  38. 38.
    Bending JJ, Viberti CG, Wakin RJ, et al.: Clinical proteinuria and renal function in diabetes, education and the effect of glycemic control. BMJ 1993, 292:83–86.Google Scholar
  39. 39.
    Klein R, Klein BEK, Moss SE: Relation of glycemic control to diabetic microvascular complications. Ann Intern Med 1991, 37:85–101.Google Scholar
  40. 40.
    Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982, 285:685–688.PubMedGoogle Scholar
  41. 41.
    Parving HH, Andersen AR, Smidt UM, et al.: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 1:1175–1179.PubMedCrossRefGoogle Scholar
  42. 42.
    Taguma Y, Kitamoto Y, Futaki G, et al.: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985, 313:1617–1620.PubMedGoogle Scholar
  43. 43.
    DeCesaris R, Ranierei G, Flitti V, et al.: Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovas Pharmacol 1993, 22:208–214.Google Scholar
  44. 44.
    Slataper R, Vicknair N, Sadler R, et al.: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1995, 153:973–980.CrossRefGoogle Scholar
  45. 45.
    Pillion JJ: The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis 1993, 22:798–802.Google Scholar
  46. 46.
    Walker WG: Hypertension related renal injury. Am J Kidney Dis 1993, 22:164–173.PubMedGoogle Scholar
  47. 47.
    Parving HH, Smidt UM, Hommel E: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993, 22:188–195.PubMedGoogle Scholar
  48. 48.
    Lewis E, Hunsicker L, Bain R, et al.: The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462.PubMedCrossRefGoogle Scholar
  49. 49.
    Lebovitz HE, Wiegmann TB, Coraan A, et al.: Renal protective effects of enalapril in hypertensive NIDDM. Kidney Int 1994, 45:S150-S155.Google Scholar
  50. 50.
    Bakris G, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: the importance of therapeutic selection. Kidney Int 1992, 41:912–919.PubMedGoogle Scholar
  51. 51.
    Yokoyama H, Tomonaya O, Hirayama M, et al.: Predictors of the progression of diabetic nephropathy and the beneficial effect of ACE-inhibitors in NIDDM patients. Diabetologia 1997, 40:405–411.PubMedCrossRefGoogle Scholar
  52. 52.
    Kasiske BL, Kall RSN, Ma JZ, et al.: Effects of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 1993, 118:129–138.PubMedGoogle Scholar
  53. 53.
    Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmcological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925–1930.PubMedCrossRefGoogle Scholar
  54. 54.
    Lacourciere Y, Nadeau A, Poirier L: Captopril or conventional therapy in hypertensive type II diabetes: three year analysis. Hypertension 1995, 21:786–794.Google Scholar
  55. 55.
    Liou HH, Huang T, Capese VM: Effect of long-term therapy with captopril on proteinuria and renal function in patients with NIDDM. Nephrol 1995, 69:41–48.Google Scholar
  56. 56.
    Cooper ME: Antihypertensive therapy and diabetic microvascular disease. Clin Exp Hypertens 1997, 19:769–778.PubMedGoogle Scholar
  57. 57.
    Maki DD, Ma JZ, Louis TA, et al.: Effect of antihypertensive agents on the kidney. Arch Intern Med 1995, 155:1073–1082.PubMedCrossRefGoogle Scholar
  58. 58.
    Parving HH: Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994, 43:1108–1113.PubMedCrossRefGoogle Scholar
  59. 59.
    Weidmann P, Schneider M, Bohlen CM: Therapeutic efficacy of different antihypertensive drugs in human nephropathy: An updated meta-analysis. Nephrol Dial Transplant 1995, 10:39–45.PubMedGoogle Scholar
  60. 60.
    Weidman P, Bohlen CM, de Courten M: Effects of antihypertensive therapy on the kidney in patients with diabetes. Ann Intern Med 1993, 118:129–138.Google Scholar
  61. 61.
    Bjorck S, Mulec H, Johnsen SA: Contrasting effects of enalapril and metorolol on proteinuria in diabetic nephropathy. BMJ 1990, 300:900–904.Google Scholar
  62. 62.
    Mulec H, Johnsen SA, Bjorck S: Long-term enalapril treatment in diabetic nephropathy. Kidney Int 1994, 45:S141-S145.Google Scholar
  63. 63.
    Bakris GL, Copley JB, Vincknair N: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50:1641–1650.PubMedCrossRefGoogle Scholar
  64. 64.
    Schneider M, Lerch M, Papiri M: Metabolic neutrality of combined Verapamil-Trandolapril as opposed to beta-blockerlow-dose chlorthalidone in hypertensive type 2 diabetics. J Hypertens 1996, 14:669–677.PubMedCrossRefGoogle Scholar
  65. 65.
    Ravid M, Savin H, Itzhak J, et al.: Long-term stabilizing effect of ACE-inhibition on plasma creatinine and proteinuria in normotensive type II diabetics. Ann Intern Med 1993, 118:577–581.PubMedGoogle Scholar
  66. 66.
    Hebert LA, Bain RP, Verme D, et al.: Remission of nephrotic proteinuria with type 1 diabetes. Kidney Int 1994, 46:1688–1693.PubMedCrossRefGoogle Scholar
  67. 67.
    Perico N, Amuchastegui CS, Malanchini B, et al.: ACE-inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late structural damage. Exp Nephrol 1994, 2:2210–228.Google Scholar
  68. 68.
    Rodby R, Furth L, Lewis E: An economic analysis of captopril in the treatment of diabetic nephropathy. Am J Soc Nephrol 1994, 5:382.Google Scholar
  69. 69.
    Nielsen FS, Rossing P, Gall MA.: Long term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with nephropathy. Diabetes 1997, 46:1182–1188.PubMedCrossRefGoogle Scholar
  70. 70.
    Lapuz MHS: Diabetic nephropathy. Med Clin North Am 1997, 81:679–688.PubMedCrossRefGoogle Scholar
  71. 71.
    Bakris GL: Hypertension in diabetic patients. an overview of interventional studies to preserve renal function. Am J Hypertens 1994, 6:140S-147S.Google Scholar
  72. 72.
    Parving HH, Tarnow L, Rossing P: Renal protection in diabetics: an emerging role for calcium antagonists. J Hypertens 1996, 14:S21-S25.CrossRefGoogle Scholar
  73. 73.
    Norgaard K, Jensen T, Christensen P: A comparison of spirapil and isradipine in patients with diabetic nephropathy and hypertension. Blood Pressure 1993, 2:301–308.PubMedGoogle Scholar
  74. 74.
    Bretzel RG: Prevention and slowing down the progression of diabetic nephropathy through antihypertensive therapy. J Diabetes Comp 1997, 11:112–122. Concise review of current effective antihypertensive therapies for attenuating renal decline in diabetic nephropathy.CrossRefGoogle Scholar
  75. 75.
    Taft JR, Nolan CJ, Yeung SP, et al.: Clinical and histological correlates of decline in renal function in diabetics with proteinuria. Diabetes 1994, 43:1046–1051.PubMedCrossRefGoogle Scholar
  76. 76.
    Kloke HJ, Branten AJ, Huysmans FT, et al.: Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997, 46:481–487.CrossRefGoogle Scholar
  77. 77.
    Bakris GL, Mangrum A, Copley JB: Effect of calcium channel or beta blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997, 29:744–750.PubMedGoogle Scholar
  78. 78.
    Guasch A, Parham M, Zayas CF, et al.: Contrasting effects of calcium channel blockers versus ACE-inhibitors on proteinuria in Americans with NIDDM and nephropathy. J Am Soc Nephrol 1997, 8:793–798.PubMedGoogle Scholar
  79. 79.
    Rossing P, Tarnow L, Boelskifte S, et al.: Differences between nisoldipine and lisinopril on GFR in hypertensive IDDM patients with diabetic nephropathy. Diabetes 1997, 46:481–487.PubMedCrossRefGoogle Scholar
  80. 80.
    Kloke HS, Branten AJ, Huysmans FT, et al.: Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers. Kidney Int 1998, 53:1555–1573.CrossRefGoogle Scholar
  81. 81.
    Tatti P, Pahor M, Byington R: Outcome results of the Fosinopril versus Amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597–603. Suggests that myocardial infarction might be increased in diabetics on calcium channel blockers.PubMedCrossRefGoogle Scholar
  82. 82.
    Estacio RO, Jeffers BW, Hiatt WR: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with NIDDM and hypertension. N Engl J Med 1998, 338:645–652. Randomized controlled trial that found a significantly higher incidence of myocardial infarction among those diabetics assigned to therapy with calcium antagonists than among those assigned to an ACE inhibitor.PubMedCrossRefGoogle Scholar
  83. 83.
    Pahor M, Kritchevsky SB, Zuccala G, et al.: Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998, 21:193–194.PubMedGoogle Scholar
  84. 84.
    Stanton AV: Calcium channel blockers. BMJ 1998, 316:1471–1473.PubMedGoogle Scholar
  85. 85.
    Triggle DS: Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. Am J Cardiol 1996, 78:7–12.PubMedCrossRefGoogle Scholar
  86. 86.
    Remuzzi A, Perico N, Amuchastegui CS, et al.: Short- and longterm effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993, 4:40–49.PubMedGoogle Scholar
  87. 87.
    Pitt B: Randomized trial of losartan v. captopril in patients over 65 with heart failure. Lancet 1997, 349:747–752.PubMedCrossRefGoogle Scholar
  88. 88.
    Bakris GL: Angiotensin II receptor blockers in hypertension and renal disease. Hosp Pract 1998, 33:19–22.Google Scholar
  89. 89.
    Phol M, Cooper M, Ulrey J, et al.: Safety and efficacy of irbesartan in hypertensive type II diabetics. Am J Hypertens 1997, 10:105A.Google Scholar
  90. 90.
    Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334:1649–1655.PubMedCrossRefGoogle Scholar
  91. 91.
    Collins R, Peto R, MacMahon S: Blood pressure, stroke and coronary disease: overview of randomized drug trials in their epidemiologic context. Lancet 1990, 1:827–838.CrossRefGoogle Scholar
  92. 92.
    SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in old persons with isolated systolic hypertension. JAMA 1991, 265:3255–3264.CrossRefGoogle Scholar
  93. 93.
    Weidman P, Teuscher AU, Bohler L: Treatment of elevated blood pressure in diabetic patients. J Diabetes Comp 1997, 11:92–99.CrossRefGoogle Scholar
  94. 94.
    Brown S, Walton C, Crawford P, et al.: Comparative renal hemodynamic effects of an ACE-inhibitor or calcium antagonist on progression of diabetic nephropathy. Kidney Int 1993, 42:1210–1218.Google Scholar
  95. 95.
    Raij L: Effects of ACE-inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Nephrol Dial Transplant 1995, 10:23–27.PubMedGoogle Scholar
  96. 96.
    Carminges PK, Navar CG: Disparate effects of calcium channel blockade in efferent arteriolar responses to ANG II. Am J Physiol 1989, 256:1015–1020.Google Scholar
  97. 97.
    Schneider M, Lerch M, Papiri M, et al.: Metabolic neutrality of combined verapamil-trandolapril treatment in hypertensive type 2 diabetes. J Hypertens 1996, 14:667–669.CrossRefGoogle Scholar
  98. 98.
    Mehler PS, Schrier RW: Antihypertensive therapy in patients with diabetic nephropathy. Kidney Blood Pres Res 1997, 20:74–81.CrossRefGoogle Scholar
  99. 99.
    Martin J, Kendall K, Lynch P, et al.: Beta-blockers and sudden cardiac death. Am J Cardiol 1995, 123:358–367.Google Scholar
  100. 100.
    Rossing P, Hommel E, Smidt UM, et al.: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994, 45:S145-S149.Google Scholar
  101. 101.
    Psaty BM, Smith NL, Siscovick DS: Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997, 277:739–745.PubMedCrossRefGoogle Scholar
  102. 102.
    American Diabetes Association: Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994, 17:1357–1361.Google Scholar
  103. 103.
    Viberti GC, Mogensen CE, Passa P, et al.: St. Vincent Declaration 1994: Guidelines for the prevention of diabetic renal failure. In The Kidney and Hypertension in Diabetes Mellitus, edn 2. Edited by Mogensen CE. Boston: Makluwer; 1994:515–517.Google Scholar
  104. 104.
    Hansson L, Zanchetti A. Carruthers SG, et al.: Effect of intensive blood pressure lowering in patients with hypertension. Principal results of the HOT randomized trial. Lancet 1998, 351:1755–1727. Demonstrates significant benefit of aggressive blood pressure control in diabetics.PubMedCrossRefGoogle Scholar
  105. 105.
    Neaton JD, Grimm RH, Prineas R, et al.: Treatment of mild hypertension study. JAMA 1993, 270:713–724.PubMedCrossRefGoogle Scholar
  106. 106.
    Parving H: Benefits and cost of antihypertensive treatment in overt diabetic nephropathy. J Hypertens 1998, 16:S99-S101.Google Scholar
  107. 107.
    Ravid M, Brosh D, Levi Z: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes. Ann Intern Med 1998, 128:982–988.PubMedGoogle Scholar
  108. 108.
    Consensus Statement: Treatment of hypertension in diabetes. Diabetes Care 1996, 19:S107–S113.Google Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Philip S. Mehler
    • 1
  • Robert W. Schrier
    • 2
  1. 1.Denver Health Medical CenterUniversity of Colorado Health Sciences CenterDenverUSA
  2. 2.Department of MedicineUniversity of Colorado Health Sciences CenterDenverUSA

Personalised recommendations